EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 3, 2008, Pages 303-310

  Fong, Thomas ^a   Morgensztern, Daniel ^a,b,c   Govindan, Ramaswamy ^a,b,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Box 8056   (United States)

Author keywords

EGFR TK Inhibitors; First line Therapy; NSCLC

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM; TAXANE DERIVATIVE;

ADVANCED CANCER; CANCER THERAPY; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MUTATION; PRIORITY JOURNAL; REVIEW;

EID: 43249117388     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181645477     Document Type: Article

References (55)

1. A Jemal R Siegel E Ward Cancer statistics, 2006 CA Cancer J Clin 56 2006 106 130
2. DM Parkin F Bray J Ferlay Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
3. R Govindan N Page D Morgensztern Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 24 2006 4539 4544
4. A Spira DS Ettinger Multidisciplinary management of lung cancer N Engl J Med 350 2004 379 392
5. JH Schiller D Harrington CP Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
6. F Fossella JR Pereira J von Pawel Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group J Clin Oncol 21 2003 3016 3024
7. K Kelly J Crowley PA Bunn Jr Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218
8. RA Figlin JJ Crowley EL Jacobs Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group Cancer 78 1996 998 1003
9. J Schlessinger Ligand-induced, receptor-mediated dimerization and activation of EGF receptor Cell 110 2002 669 672
10. D Morgensztern R Govindan Is there a role for cetuximab in non small cell lung cancer? Clin Cancer Res 13 2007 4602s 4605s
11. MH Cohen GA Williams R Sridhara United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets Clin Cancer Res 10 2004 1212 1218
12. JR Johnson M Cohen R Sridhara Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen Clin Cancer Res 11 2005 6414 6421
13. FA Shepherd J Rodrigues Pereira T Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
14. M Fukuoka S Yano G Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 2003 2237 2246
15. N Thatcher A Chang P Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537
16. VA Miller MG Kris N Shah Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J Clin Oncol 22 2004 1103 1109
17. G Giaccone M Gallegos Ruiz T Le Chevalier Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study Clin Cancer Res 12 2006 6049 6055
18. R Rosell C Daniel R Ramlau Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) J Clin Oncol 22 2004 Abstract 7012.
19. RS Herbst K Chansky K Kelly A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342 J Clin Oncol 25 2007 Abstract 7545.
20. CA Butts D Bodkin EL Middleman Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC) J Clin Oncol 25 2007 Abstract 7539.
21. TJ Lynch T Patel L Dreisbach A randomized multicenter phase III study of cetuximab (Erbitux) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC) J Thorac Oncol 2 2007 S340 S341
22. J von Pawel K Park JR Pereira Phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vinorelbine as first-line treatment for patients with epidermal growth factor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC) (FLEX) J Clin Oncol 24 2006 Abstract 7109.
23. TJ Lynch DW Bell R Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
24. JG Paez PA Janne JC Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
25. C Gridelli MA Bareschino C Schettino Erlotinib in non-small cell lung cancer treatment: current status and future development Oncologist 12 2007 840 849
26. FR Hirsch M Varella-Garcia PA Bunn Jr Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer J Clin Oncol 24 2006 5034 5042
27. MS Tsao A Sakurada JC Cutz Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
28. L Crino P Zatloukal M Reck Gefitinib (IRESSA) versus vinorelbine in chemonaive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study J Thorac Oncol 2 2007 S341
29. JY Douillard E Kim V Hirsh Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST): PRS-02 J Thorac Oncol 2 2007 S305 S306
30. W Pao TY Wang GJ Riely KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 2005 e17
31. DH Lee JY Han HG Lee A phase II study of gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in lifetime non-smokers J Clin Oncol 23 16S 2005 Abstract 7072.
32. F Cappuzzo C Ligorio PA Janne Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial J Clin Oncol 25 2007 2248 2255
33. F Cappuzzo E Magrini GL Ceresoli Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer J Natl Cancer Inst 96 2004 1133 1141
34. RS Herbst D Prager R Hermann TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
35. U Gatzemeier A Pluzanska A Szczesna Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 2007 1545 1552
36. G Giaccone RS Herbst C Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1 J Clin Oncol 22 2004 777 784
37. RS Herbst G Giaccone JH Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2 J Clin Oncol 22 2004 785 794
38. H Asahina K Yamazaki I Kinoshita A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations Br J Cancer 95 2006 998 1004
39. L Paz-Ares JM Sanchez A Garcia-Velasco A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor J Clin Oncol 24 2006 Abstract 7020.
40. LV Sequist RG Martins D Spigel iTarget: a phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors J Clin Oncol 15 18S 2007 Abstract 7504.
41. ClinicalTrials.gov : www.clinicaltrials.gov . Accessioned October 26, 2007.
42. DM Jackman BY Yeap NI Lindeman Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer J Clin Oncol 25 2007 760 766
43. C Gridelli The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study Oncologist 6 suppl 1 2001 4 7
44. C Gridelli P Maione A Illiano Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies J Clin Oncol 25 2007 4663 4669
45. D Swinson S Williams K Beddard Phase II trial of first-line gefitinib in patients unsuitable for chemotherapy with stage III/IV non-small-cell lung cancer J Clin Oncol 23 16S 2005 Abstract 7256.
46. R Lilenbaum R Axerold S Thomas Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2 J Clin Oncol 24 18S 2006 Abstract 7022.
47. PJ Hesketh K Chanksy AJ Wozniak Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2: A SWOG phase II trial (S0341) J Clin Oncol 25 18S 2007 Abstract 7536.
48. DR Spigel JD Hainsworth ER Burkett Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial Clin Lung Cancer 7 2005 127 132
49. VA Miller FR Hirsch DH Johnson Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities J Clin Oncol 23 2005 3288 3293
50. VA Miller J Patel N Shah The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC): preliminary results of a phase II trial Proc Am Soc Clin Oncol 22 2003 Abstract 2491.
51. HL West WA Franklin J McCoy Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126 J Clin Oncol 24 2006 1807 1813
52. A Bearz R Talamini E Vaccher Ca-15. 3 antigen as predictor of response to EGFR inhibitors in patients with bronchio-alveolar carcinoma J Clin Oncol 25 18S 2007 Abstract 18151.
53. J Cadranel E Quoix P Debove IFCT0401 trial: Phase II study of gefitinib administered as first line treatment in non-resectable pneumonic-type adenocarcinoma (P-ADC) J Clin Oncol 24 18S 2006 Abstract 7186.
54. M Reck E Buchholz KS Romer Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer Clin Lung Cancer 7 2006 406 411
55. S Niho K Kubota K Goto First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study J Clin Oncol 24 2006 64 69